News & Updates
Filter by Specialty:
Conversion to resectability uncommon in trials of unresectable mCRC patients
In clinical trials of patients with unresectable metastatic colorectal cancer (mCRC), conversion to resectability (C2R) rarely happens, reveals a study.
Conversion to resectability uncommon in trials of unresectable mCRC patients
04 Aug 2022
Abiraterone-olaparib confers clinical benefit for mCRPC patients
The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.
Abiraterone-olaparib confers clinical benefit for mCRPC patients
04 Aug 2022
70-gene signature identifies ultra-low risk of distant recurrence in breast cancer patients
MammaPrint, a signature test that includes 70 genes, appears to accurately identify hormone receptor-positive breast cancer (HR+BC) patients who are at ultra-low risk of distant recurrence, reports a recent study.
70-gene signature identifies ultra-low risk of distant recurrence in breast cancer patients
04 Aug 2022
Is pre-emptive pharmacogenetic testing in CRC patients viable within a community oncology clinic?
A recent study has shown that it is possible to implement pre-emptive pharmacogenetic testing into a community-based oncology clinic with results interpretation available for colorectal cancer patients before their scheduled initiation of chemotherapy.